FWP - Forward Pharma A/S

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
0.0000 (0.00%)
At close: 3:41PM EDT
Stock chart is not supported by your current browser
Previous Close0.9300
Bid0.0000 x 1300
Ask0.9800 x 800
Day's Range0.9300 - 0.9555
52 Week Range0.7100 - 3.4400
Avg. Volume6,352
Market Cap44.209M
Beta (3Y Monthly)3.45
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2017-09-12
1y Target EstN/A
Trade prices are not sourced from all markets
Press Releases
  • GlobeNewswire3 months ago

    Forward Pharma Reports Financial and Operational Results from the Year Ended December 31, 2018

    Forward Pharma A/S (FWP) (“We,” “Forward” or the “Company” and, together with its subsidiaries, the “Group”), today reported consolidated financial results for the year ended December 31, 2018. During the year ended December 31, 2017, we recognized as revenue the $1.25 billion nonrecurring non-refundable fee (“Non-refundable Fee”) that was received during February 2017 in connection with the Settlement and License Agreement (“License Agreement”) entered into with two wholly owned subsidiaries of Biogen, Inc. (collectively, “Biogen”).

  • GlobeNewswire3 months ago

    Forward Pharma to Participate in the DKBIO2019 Life Science Investor Conference

    Forward Pharma A/S (FWP) (the “Company”) today announced that Dr. Claus Bo Svendsen, the Company’s Chief Executive Officer, will participate in the DKBIO2019 life science investor conference in New York, NY. Dr. Svendsen will present a corporate update on Thursday, April 11, 2019 at 1:00 PM ET and will be available for one-on-one meetings. Forward Pharma A/S is a Danish biopharmaceutical company that commenced development in 2005 of a proprietary formulation of DMF for the treatment of inflammatory and neurological indications.

  • We're sorry this is all we were able to find about this topic.